Integra LifeSciences Holdings Co. (NASDAQ: IART) Expected to Earn $ 3.18 per Share for Fiscal 2021
Integra LifeSciences Holdings Co. (NASDAQ: IART) – Stock analysts at Jefferies Financial Group released their fiscal 2021 earnings estimates for Integra LifeSciences shares in a research note to investors on Thursday, January 6. Jefferies Financial Group analyst F. Pinal expects the life sciences company to post earnings of $ 3.18 per share for the year. Jefferies Financial Group also released Integra LifeSciences’ earnings estimates for the fourth quarter of 2021 at $ 0.84 EPS, Q1 2022 earnings at $ 0.82 EPS, Q2 2022 earnings at $ 0.89 EPS, earnings Q3 2022 at $ 0.90 EPS, Q4 2022 profits at $ 0.94 EPS, FY2022 profits at $ 3.55 EPS. , Profit for fiscal 2023 at $ 3.94 EPS, earnings for fiscal 2024 at $ 4.45 EPS, and earnings for fiscal 2025 at $ 5.07 EPS. Integra LifeSciences (NASDAQ: IART) last released its quarterly earnings data on Monday, November 1. The life sciences company reported earnings per share (EPS) of $ 0.86 for the quarter, beating Zacks’ consensus estimate of $ 0.72 by $ 0.14. Integra LifeSciences delivered a return on equity of 17.33% and a net margin of 14.19%. The company posted revenue of $ 386.86 million in the quarter, compared to $ 384.47 million expected by analysts. During the same period last year, the company posted earnings of $ 0.80 per share. The company’s revenue grew 4.5% year-over-year.
The IART has been the subject of a number of other research reports. JPMorgan Chase & Co. upgraded Integra LifeSciences from an “underweight” to a “neutral” rating and set a target price of $ 75.00 on the stock in a research note on Friday, December 17th. Credit Suisse Group raised its price target on Integra LifeSciences from $ 84.00 to $ 87.00 and gave the stock an “outperformance” rating in a Wednesday, November 3 research note. JMP Securities reaffirmed a “buy” note on Integra LifeSciences shares in a research note on Wednesday, November 3. Finally, BTIG Research downgraded Integra LifeSciences from a âbuyâ rating to a âneutralâ rating in a research note on Wednesday, September 15. Six equity research analysts rated the stock with a conservation rating and three issued a buy rating for the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $ 77.22.
NASDAQ: IART opened at $ 65.86 on Monday. The stock has a market cap of $ 5.58 billion, a P / E ratio of 25.93, a PEG ratio of 1.47 and a beta of 1.20. The stock has a 50-day simple moving average of $ 67.28 and a 200-day simple moving average of $ 69.09. The company has a current ratio of 3.32, a rapid ratio of 2.33, and a debt ratio of 0.92. Integra LifeSciences has a one-year minimum of $ 61.85 and a one-year maximum of $ 77.40.
In other Integra LifeSciences news, major shareholder Tru St Partnership, LP sold 200,000 shares of Integra LifeSciences in a transaction dated Wednesday, October 20. The stock was sold at an average price of $ 69.81, for a total trade of $ 13,962,000.00. The sale was disclosed in a filing with the SEC, which is available through this link. In addition, Executive Vice President Michael J. Mcbreen sold 3,450 shares of the company in a transaction dated Friday, November 5. The shares were sold for an average price of $ 71.59, for a total value of $ 246,985.50. Disclosure of this sale can be found here. In the past three months, insiders have sold 282,725 shares of the company valued at $ 19,669,586. 4.20% of the shares are currently held by insiders of the company.
Several large investors have recently changed their positions in IART. Amundi Pioneer Asset Management Inc. acquired a new position in Integra LifeSciences shares in the 1st quarter for a value of approximately $ 329,000. Envestnet Asset Management Inc. increased its position in Integra LifeSciences by 1.1% in the second quarter. Envestnet Asset Management Inc. now owns 55,763 shares of the life sciences company valued at $ 3,805,000 after purchasing an additional 599 shares in the last quarter. Duality Advisers LP purchased a new stake in Integra LifeSciences in the second quarter for a value of approximately $ 898,000. Skandinaviska Enskilda Banken AB publ increased its position in Integra LifeSciences by 2.9% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 24,352 shares of the life sciences company valued at $ 1,662,000 after purchasing an additional 695 shares in the last quarter. Finally, Edgestream Partners LP purchased a new stake in Integra LifeSciences in the second quarter for a value of approximately $ 4,253,000. 87.70% of the shares are currently held by institutional investors.
Company Profile Integra LifeSciences
Integra LifeSciences Holdings Corp. is engaged in the manufacture and sale of medical instruments, devices and equipment. It operates through the Codman Specialty Surgical, Orthopedics and Tissue Technologies segments. Codman Specialty Surgical segment refers to the neurosurgery business of the company, which sells a full line of products for neurosurgery and neuro-critical care such as tissue ablation equipment, dural repair products, cerebrospinal fluid management devices, intracranial monitoring equipment and cranial stabilization equipment; and the precision tools and instruments business, which sells model surgical and lighting instruments and products to hospitals, surgical centers and dental, podiatry and veterinary surgeries.
See also: strangles
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [emailÂ protected]
Should you invest $ 1,000 in Integra LifeSciences now?
Before you consider Integra LifeSciences, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold of … and Integra LifeSciences was not on the list.
While Integra LifeSciences currently has a âHoldâ rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here